NCT04890938 Sputum-guided Treatment With Comprehensive Care Management in COPD - A Randomized-controlled Trial
| NCT ID | NCT04890938 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McMaster University |
| Condition | COPD |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2022-05-27 |
| Primary Completion | 2025-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 128 participants in total. It began in 2022-05-27 with a primary completion date of 2025-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic obstructive pulmonary disease (COPD) is a lung condition affecting 1 in 6 Canadians and does not have a cure. Flare-ups of COPD are the most common reason someone goes to hospital in Canada. This is made worse because within 30-days of having a flare-up, 1 in 5 patients will come back to hospital for the same problem. Flare-ups of COPD often have many causes and these are different person to person. Sometimes it is related to behaviours such as smoking or not using medicines properly. Other times, it is from lung inflammation. Education programs that help people learn about their disease and maintain healthy behaviours, and using phlegm to decide on which medicines will be useful, have been studied separately and appear to work, but many people still have flare-ups. To help fix this problem, we need to look carefully at each patient, to make sure they are on the right medicine but also have the right behaviours and support to benefit from medical care. The goal of this project is to see if patients who are taught the right behaviours and have their lung inflammation controlled with the right medicines will have fewer COPD flare-ups than those who get normal care.
Eligibility Criteria
Inclusion Criteria: * \>=2 exacerbations of COPD in the last 12-months, FEV1/FVC\<0.7 or radiologic emphysema, with a \>-10 pack-year smoking history Exclusion Criteria: * severe mental illness not controlled by medication or life-expectancy less than 6-months
Contact & Investigator
Terence Ho, MB, MSc
PRINCIPAL INVESTIGATOR
St. Joseph's Healthcare Hamilton
Frequently Asked Questions
Who can join the NCT04890938 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04890938 currently recruiting?
Yes, NCT04890938 is actively recruiting participants. Contact the research team at hot4@mcmaster.ca for enrollment information.
Where is the NCT04890938 trial being conducted?
This trial is being conducted at Hamilton, Canada, Hamilton, Canada.
Who is sponsoring the NCT04890938 clinical trial?
NCT04890938 is sponsored by McMaster University. The principal investigator is Terence Ho, MB, MSc at St. Joseph's Healthcare Hamilton. The trial plans to enroll 128 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.